Managing Side Effects of BCMA-Targeting Bispecifics in R/R MM

Video

Maria-Victoria Mateos, MD, PhD, reviews how she manages the side effects of teclistamab, including cytokine release syndrome, in patients with relapsed/refractory multiple myeloma.

Recent Videos
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
Although a similar proportion achieved MRD negativity at the 10 to the –6 power, not enough studies have analyzed MRD at this level for multiple myeloma.
Unique toxicities presented with talquetamab tend to get progressively better as the treatment course continues, according to Prerna Mewawalla, MD.
Related Content